Re-analysis of data from a phase 3 randomized controlled trial of IL-1 antagonist (Anakinra) in sepsis demonstrated significant survival benefit in patients with hyperinflammation, without increased adverse events [24]. The gene discussed is IL1B; the disease is Sepsis.